Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

Systemic Lupus Erythematosus Clinical Trial

Official title:

A Pilot Study of High-Dose Immunosuppression Followed by Infusion of CD34-Selected Autologous or Syngeneic Peripheral Blood Stem Cells for Treatment of Refractory Autoimmune Disorders

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00010335
• Other study ID #: 1353.00
• Secondary ID: FHCRC-1353.00199
• Status: Completed
• Phase: Phase 1
• First received: February 2, 2001
• Last updated: March 4, 2015
• Start date: November 2000
• Est. completion date: May 2011

Study information

• Verified date: March 2015
• Source: Fred Hutchinson Cancer Research Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

OBJECTIVES: I. Determine the safety and long term complications of total body irradiation in combination with cyclophosphamide, anti-thymocyte globulin, and autologous CD34-selected peripheral blood stem cell (PBSC) transplantation in children with refractory autoimmune disorders.

II. Determine the efficacy of this treatment regimen in these patients. III. Determine the reconstitution of immunity after autologous CD34-selected PBSC transplantation in these patients.

IV. Determine engraftment of autologous CD34-selected PBSC in these patients.

Description:

PROTOCOL OUTLINE: This is a multicenter study. Patients receive filgrastim (G-CSF) subcutaneously daily until peripheral blood stem cell (PBSC) collection is completed. CD34+ cells are separated from the rest of the PBSCs.

Patients undergo total body irradiation twice daily on days -5 and -4. Patients receive anti-thymocyte globulin IV on days -5, -3, -1, 1, 3, and 5 and cyclophosphamide IV on days -3 and -2. CD34-selected PBSCs are reinfused on day 0. Patients receive G-CSF IV daily beginning on day 0 and continuing until blood counts recover.

Patients are followed annually for 5 years and then every 5 years thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: May 2011
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years to 18 Years

Eligibility

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

• Diagnosis of 1 of the following based on American College of Rheumatology (ACR) Criteria: Severe juvenile rheumatoid arthritis (systemic onset or polyarticular course) Juvenile systemic lupus erythematosus Systemic sclerosis Dermatomyositis

• Refractory to standard or aggressive therapy OR unacceptable toxicity from standard therapy

• Reasonable expectation of possible improvement as evidenced by a good potential for rehabilitation therapy and adequate social factors

• No serious CNS damage that would preclude significant functional recovery

--Prior/Concurrent Therapy--

• Chemotherapy: At least 4 weeks since prior methotrexate or cyclophosphamide

• Endocrine therapy: At least 4 weeks since prior intra-arterial steroids Juvenile rheumatoid arthritis patients should continue steroids without taper throughout mobilization and harvest of stem cells If receiving corticosteroids, must be continued without taper

Other:

• At least 4 weeks since prior anti-inflammatory agents such as non-steroidal anti-inflammatory drugs (NSAIDs) or sulfasalazine

• At least 4 weeks since prior cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, penicillamine, or etanercept

--Patient Characteristics--

• Life expectancy: At least 30 days

• Hematopoietic: Absolute neutrophil count at least 1,000/mm3 OR Platelet count at least 100,000/mm3 No bone marrow aspirate or biopsy consistent with production defect (depletion of neutrophil precursors or megakaryocytes) No myelodysplasia

• Hepatic: Bilirubin no greater than 2.5 mg/dL AST no greater than 300 U/L on two sequential tests No severe liver dysfunction within past month No active hepatitis A, B, or C

• Renal: No end-stage glomerulonephritis or renal disease Creatinine clearance at least 40 mL/min

• Cardiovascular: No uncontrolled malignant arrhythmia No New York Heart Association class III or IV congestive heart failure Ejection fraction at least 50%

• Pulmonary: DLCO at least 45% (DLCO at least 70% for patients with pulmonary disease caused by documented processes other than primary autoimmune disorder, such as infectious pneumonia or aspiration pneumonia) No severe pulmonary hypertension (PAP greater than 50) without potential for significant improvement

Other:

• No medical or psychosocial reasons that would make hematopoietic stem cell collection intolerable

• No increased anesthetic risks

• No fever higher than 39 degrees C

• No positive serology for toxoplasmosis

• No active life threatening infection not responsive to therapy

• No other disease or organ dysfunction that would limit survival

• No known hypersensitivity to murine or equine proteins

• No known primary immunodeficiency disease HIV negative

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arthritis, Juvenile
• Arthritis, Rheumatoid
• Autoimmune Diseases
• Dermatomyositis
• Juvenile Rheumatoid Arthritis
• Lupus Erythematosus, Systemic
• Scleroderma, Diffuse
• Scleroderma, Systemic
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Intervention

Procedure:
• Stem Cell Transplantation
Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.

Device:
• CD34 selection
CD34+ cells are separated from the rest of the peripheral blood stem cells.

Locations

Country	Name	City	State
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality		Annually for 5 years and then every 5 years thereafter	Yes
Secondary	Immune reconstitution, engraftment, efficacy, late-effects		Annually for 5 years and then every 5 years thereafter	Yes